

Firdapse (amifampridine)
Effective 08/01/2025

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Medical Benefit Pharmacy Benefit	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
Exceptions	N/A		

Overview

Firdapse (amifampridine) is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.

Coverage Guidelines

Authorization may be reviewed for members new to the plan within the past 90 days who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

OR

Authorization may be granted for members when ALL the following criteria are met:

1. Diagnosis of symptomatic Lambert-Eaton myasthenic syndrome (LEMS)
2. Member is 6 years of age or older
3. Requested medication is prescribed by or in consultation with a neurologist
4. The member meets one of the following laboratory results confirming the diagnosis:
 - a. Neurophysiology study tests
 - b. Positive anti-P/Q type voltage-gated calcium channel antibody test

Continuation of Therapy

Requests for reauthorization will be approved when the following criteria are met:

1. Documentation is submitted demonstrating an improvement of member's condition.

Limitations

1. Initial approvals will be for 6 months.
2. Reauthorizations will be for 12 months
3. The following quantity limits apply:

Drug Name and Dosage Form	Quantity Limitations
Firdapse (amifampridine) 10mg tablet	240 tablets per 30 days

References

1. Firdapse (amifampridine) [prescribing information]. Coral Gables, FL: Catalyst Pharmaceuticals, Inc; May 2024.

2. Lindquist S, Stangel M. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. *Neuropsychiatr Dis Treat*. 2011;7:341-349. doi: 10.2147/NDT.S10464.[PubMed 21822385]
3. Pelufo-Pellicer A, Monte-Boquet E, Romá-Sánchez E, Casanova-Sorní C, Poveda-Andrés JL. Fetal exposure to 3,4-diaminopyridine in a pregnant woman with congenital myasthenia syndrome. *Ann Pharmacother*. 2006;40(4):762-766.[PubMed 16537815]
4. Wirtz PW, Titulaer MJ, Gerven JM, Verschueren JJ. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome. *Expert Rev Clin Immunol*. 2010;6(6):867-874. doi: 10.1586/eci.10.57.[PubMed 20979551]

Review History

09/16/2020 – Reviewed and approved Sept P&T Mtg. Effective 11/01/20.

11/16/2022 – Reviewed for Nov P&T. Separated out MH vs Comm/Exch. Removed Ruzurgi from criteria as product is discontinued. Effective 01/01/2023.

11/15/2023 – Reviewed and Updated; Updated age requirement from 18 years and older to > 6 years. Effective 1/1/2024

05/14/2025 – Reviewed and updated at May P&T. Updated language for members who are new to the plan. Clarified documentation requirements. Effective 08/01/2025.

